GCCL and Frontage Laboratories Announce Strategic Collaboration to Strengthen Global Clinical Trial Capabilities

YONGIN, South Korea, Sept. 24, 2025 /PRNewswire/ -- GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, and Frontage Laboratories, Inc., a USA based full-service contract research organization (CRO), announced on September 23 that they had signed a strategic Memorandum of Understanding (MOU) pursuant to which they intend to explore ways to strengthen their presence in the global clinical trial market.

In signing the MOU, GCCL and Frontage intend to consider opportunities to leverage the complementary services and networks of both companies to enhance competitiveness, particularly in the United States and Asia-Pacific (APAC) regions, while driving mutual growth. In particular, during the signing ceremony, the two companies reaffirmed their commitment to collaboration and discussed opportunities for cooperation including joint clinical trial services in the U.S.A. and APAC regions, co-marketing and project support initiatives, development of new business opportunities, and additional initiatives.

In addition, GCCL and Frontage will combine their respective regional expertise and global networks to collaborate in executing clinical trial projects while increasing efficiency and differentiation of services for clients worldwide. In doing so, GCCL would expect to further strengthen its global capabilities, while Frontage would look to bolster its clinical trial support system in the APAC region.

"Through this MOU, Frontage is hoping to develop a relationship with GCCL with the goal of reinforcing its presence in the APAC market and work closely with GCCL to providing faster and more efficient support for global clinical trials," said Dr. Nan Zhang, MD. PhD., Senior Vice President of Frontage. "By finding paths to collaborate and leverage the expertise and client networks of both companies, we would hope to further enhance the global clinical trial ecosystem and deliver high-quality, trusted services to our customers."

KwanGoo Cho, CEO of GCCL, added, "We are hoping to develop a strategic relationship with Frontage focused on a spirit of collaboration. By working together, GCCL's bioanalytical and central lab expertise in APAC and Frontage's global capabilities may create new growth opportunities in the global clinical trial market for both companies. As always, we continue to aim to set a new standard in clinical trial execution and deliver meaningful analytical outcomes to our clients."

About GCCL (Global Clinical Central Lab)
GCCL, a subsidiary of the GC Group, is a leading clinical trial sample analysis provider offering an integrated "one-stop lab solution" with central, bioanalysis, and BSL-3 labs under one system. With tailored solutions, GCCL delivers precise and efficient analytical services across all phases of clinical trials, solidifying its position as a trusted partner in new drug development. Leveraging advanced platforms and LIMS, the company supports partners across Asia and beyond with customized and compliant solutions. In recognition of its leadership, GCCL recently received Frost & Sullivan's 2025 Best Practices Customer Value Leadership Award in the Asia-Pacific clinical sample analysis services industry. For more details, visit: www.eng.gccl.co.kr.

About Frontage Laboratories, Inc.
Frontage Holdings Corp (1521.HK), together with its wholly owned subsidiary Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) which provides integrated, science-driven, product development services from drug discovery to late phase clinical process to enable biopharmaceutical companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions. For more details, visit: www.frontagelab.com.

GC Biopharma & GCCL Contacts (Media)

Sohee Kim
[email protected]

Yelin Jun
[email protected]

Yoonjae Na
[email protected]

HyeYeon Woo
[email protected]

SOURCE GCCL